Abstract
Endothelial monocyte-activating polypeptide (EMAP) II is a unique cytokine, also known as p43, the active mature form of which exhibits antiangiogenic properties in vivo and in vitro. The proteolytic enzymes associated with the cleavage and release of the active mature form, however, remain unclear. Here we show that, in contrast to prior observations, purified pro-EMAP II is not cleaved by either caspase-3 or -7 in vivo or in vitro. Thus other proteolytic processes, which allow it to induce apoptosis via caspase-3 activation in migrating and dividing endothelium, may be involved in the release of the active mature EMAP II.
Original language | English (US) |
---|---|
Pages (from-to) | L1239-L1244 |
Journal | American Journal of Physiology - Lung Cellular and Molecular Physiology |
Volume | 282 |
Issue number | 6 26-6 |
DOIs | |
State | Published - 2002 |
Keywords
- Antiangiogenesis
- Caspase-7
- Endothelial monocyte activating polypeptide
- Endothelial monocyte-activating polypeptide II
- Neovascularization
- p43
ASJC Scopus subject areas
- Physiology
- Pulmonary and Respiratory Medicine
- Physiology (medical)
- Cell Biology